Cencora to take majority control of OneOncology to expand cancer services

Core Viewpoint - U.S. drug distributor Cencora is acquiring majority control of cancer care network OneOncology in a deal valued at $7.4 billion, aiming to expand its services in the oncology sector [1] Group 1: Acquisition Details - Cencora will take majority control of OneOncology, enhancing its position in the cancer care market [1] - The deal values OneOncology at $7.4 billion, indicating significant investment in oncology services [1] Group 2: Strategic Implications - This acquisition reflects Cencora's strategy to broaden its service offerings in the healthcare sector, particularly in cancer care [1] - The move is expected to strengthen Cencora's capabilities and market presence in oncology [1]